All In Biotech

Drug Trial Radar · NCT07103655

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

132

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Nov 1, 2026

Study completion Jan 1, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Interventions

  • mavacamtenDrug

    Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.

  • Beta Blocker (BB) - metoprolol, bisoprolol, carvedilolDrug

    Administer an appropriate dose of beta-blockers according to the patient's tolerance.

  • diltiazemDrug

    Administer an appropriate dose of diltiazem according to the patient's tolerance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in pressure gradient during the Valsalva maneuverTime frame: Week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.